Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Ketas TJ, Chaturbhuj D, Portillo VM, Francomano E, Golden E, Chandrasekhar S, et al. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathog Immun. 2021;6(1):116-134.

Bale TA, Sait SF, Benhamida J, Ptashkin R, Haque S, Villafania L, et al. Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY). Acta Neuropathol. 2021;141(1):123-125.

Hoda RS, Hoda SA. Grossing, Staging, and Reporting-An Integrated Manual of Modern Surgical Pathology. Adv Anat Pathol. 2021;28(6):446.

Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. 2021;589(7841):299-305.

Plummer JD, Postnikoff SD, Tyler JK, Johnson JE. Selenium supplementation inhibits IGF-1 signaling and confers methionine restriction-like healthspan benefits to mice. Elife. 2021;10.

Prabhu M, Murphy EA, Sukhu AC, Yee J, Singh S, Eng D, et al. Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood. Obstet Gynecol. 2021;138(2):278-280.

Leo P, Chandramouli S, Farré X, Elliott R, Janowczyk A, Bera K, et al. Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2. Eur Urol Focus. 2021;7(4):722-732.

Jurgens EM, Ketas TJ, Zhao Z, Satlin MJ, Small CB, Sukhu A, et al. Serologic response to mRNA COVID-19 vaccination in lymphoma patients. Am J Hematol. 2021;96(11):E410-E413.

Humtsoe JO, Kim H-, Leonard B, Ling S, Keam B, Marchionni L, et al. Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. Cancer Res. 2021;81(4):1001-1013.

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.